Related Experiment Video

Updated: Aug 29, 2026

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
04:55

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease

Athena Kalyvas1, Samuel David

  • 1Centre for Research in Neuroscience, The Research Institute of the McGill University Health Centre, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4, Canada.

Neuron
|February 10, 2004
PubMed

Insights

Cytosolic phospholipase A2 (cPLA2) may drive multiple sclerosis (MS) pathology by promoting inflammation and myelin breakdown. Blocking cPLA2 significantly reduced disease onset and progression in a mouse model, suggesting it as a therapeutic target.

Area of Science:

  • Neuroimmunology
  • Enzyme function in CNS disease

Background:

  • Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS).
  • The precise mechanisms driving MS pathology, despite being considered T cell-mediated, remain unclear.
  • Experimental autoimmune encephalomyelitis (EAE) serves as a relevant animal model for studying MS.

Purpose of the Study:

  • To investigate the role of cytosolic phospholipase A2 (cPLA2) as a key mediator in the central nervous system (CNS) pathology of MS and EAE.
  • To explore the dual function of cPLA2 metabolites in promoting inflammation and myelin breakdown.

Main Methods:

  • Assessing cPLA2 expression levels within lesions of the EAE model.
  • Utilizing cPLA2 inhibitors to evaluate their impact on EAE development and progression.

Main Results:

  • cPLA2 was found to be highly expressed in EAE lesions.
  • Inhibition of cPLA2 resulted in a significant reduction in both the onset and progression of EAE.
  • cPLA2 metabolites contribute to pro-inflammatory responses and myelin breakdown.

Conclusions:

  • cPLA2 is a critical enzyme implicated in the pathogenesis of MS and EAE.
  • Targeting cPLA2 represents a promising therapeutic strategy for managing multiple sclerosis.

More Related Videos

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA210:31

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

Published on: September 26, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Asymmetric Lipid Bilayer01:35

Asymmetric Lipid Bilayer

Biological membranes show uneven distribution of different types of lipids in the inner and outer layers, resulting in transverse asymmetric membranes. The treatment of the erythrocyte membrane with the enzyme phospholipase confirmed the asymmetric nature of the lipid bilayer. The enzyme hydrolyzes lipids into fatty acids and hydrophilic groups. The phospholipase acts only on the outer layer of the membrane, while the inner layer remains intact. The phospholipase treatment resulted in 80%...
Membrane Asymmetry Regulating Transporters01:19

Membrane Asymmetry Regulating Transporters

Enzymes like flippase, floppase, and scramblase transfer phospholipids from one layer to another in the membrane, thereby affecting membrane asymmetry.
Flippase
Eukaryotic flippases are type-IV P-type ATPases or P4-ATPases belonging to P-type ATPase family proteins that are membrane-bound pumps involved in the ATP-mediated transport of ions and molecules across the membrane. Flippases flip specific phospholipids from the outer to the inner leaflet of a membrane. All P4-ATPases have one...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...